CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Acknowledge available and emerging clinical trial findings with EGFR tyrosine kinase inhibitors (TKIs) for localized non-small cell lung cancer (NSCLC) with an EGFR mutation, and identify patients for whom this novel therapeutic approach would be warranted.
  • Counsel patients with metastatic NSCLC with EGFR mutations regarding available treatment considerations, explaining the relevance of mutation type, symptomatology, sites and extent of metastases, prior therapeutic exposure and other factors.
  • Evaluate the documented efficacy of chemotherapy combined with EGFR TKI therapy, and consider the role of this strategy as first-line treatment for patients with NSCLC with EGFR mutations.
  • Appreciate the biological rationale for dual inhibition of MET and EGFR in metastatic NSCLC with an EGFR mutation, and understand recently presented data establishing the benefit of this novel strategy for patients with newly diagnosed and relapsed/refractory disease.
  • Consider the scientific justification for targeting HER3 in NSCLC with an EGFR mutation, and review the structural components, mechanism of action and available research information with novel HER3-directed antibody-drug conjugates.
  • Understand the biology of EGFR exon 20 insertion mutations, and develop a strategy to optimally employ available therapies for patients with these genetic abnormalities.
  • Recognize common side effects associated with available and emerging agents with established activity in NSCLC with EGFR mutations, and develop supportive management strategies to minimize or ameliorate these toxicities.
  • Recall the biological rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches for patients with NSCLC with EGFR mutations.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology..
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2024/EGFRNSCLC/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jonathan W Goldman, MD
  Associate Professor, UCLA Hematology and Oncology
  Director of Clinical Trials in Thoracic Oncology
  UCLA Health
  Santa Monica, California
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Gritstone bio, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Advaxis Inc,AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, Spectrum Pharmaceuticals Inc, Vaccinex Inc.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Consulting/Advisory: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc, Merck, Mirati Therapeutics Inc, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Incyte Corporation, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Navire Pharma, Takeda Pharmaceuticals USA Inc, Trizell; Data and Safety Monitoring Boards/Committees: Incyte Corporation, Mirati Therapeutics Inc, Oncocyte, Razor Genomics, Summit Therapeutics; Medical Writing Support: Novartis; Nonrelevant Financial Relationships: Medscape, OncLive, Projects in Knowledge, RTOG Foundation, VA (VALOR).
  
  Joel W Neal, MD, PhD
  Associate Professor of Medicine, Division of Oncology
  Stanford University School of Medicine
  Medical Director, Cancer Clinical Trials Office
  Stanford Cancer Institute
  Medical Director, Informatics Technology
  Stanford Medicine Cancer Center
  Stanford, California
  
  Consulting/Advisory: AbbVie Inc, Amgen Inc, AnHeart Therapeutics, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, D2G Oncology Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Sanofi, Summit Therapeutics, Surface Oncology, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Research Funding (to Institution): AbbVie Inc, Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Merck, Nektar Therapeutics, Novartis, Novocure Inc, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationships (Honoraria): BioMedical Learning Institute (BMLI), Clinical Care Options, CME Matters, HMP Education, Medical Learning Institute Inc, Medscape, MJH Life Sciences, PeerView, prIME Oncology, Projects in Knowledge, Rockpointe, The Medical Educator Consortium.
  
  Zofia Piotrowska, MD, MHS
  Assistant Professor of Medicine
  Harvard Medical School
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Merck, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Phanes Therapeutics Inc, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group; Travel Support: Janssen Biotech Inc; Nonrelevant Financial Relationship (Spouse): Employed by Blue Cross Blue Shield of Massachusetts.
  
  Joshua K Sabari, MD
  Attending Physician
  Thoracic Medical Oncology
  Assistant Professor of Medicine
  NYU Langone Health
  Perlmutter Cancer Center
  New York, New York
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc.
  
  CONSULTING CLINICAL INVESTIGATORS — Roy S Herbst, MD, PhD — Advisory Committees: AstraZeneca Pharmaceuticals LP, BioNTech SE, Bolt Biotherapeutics, Candel Therapeutics, Checkpoint Therapeutics Inc, Cybrexa Therapeutics, EMD Serono Inc, Halozyme Inc, I-Mab Biopharma, Immune-Onc Therapeutics Inc, Immunocore, Infinity Pharmaceuticals Inc, Novartis, Ocean Biomedical, Revelar Biotherapeutics, Ribon Therapeutics, STCube, Xencor; Board Member (Nonexecutive/Independent): Immunocore, Junshi Biosciences; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics Inc, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, HiberCell, I-Mab Biopharma, Immune-Onc Therapeutics Inc, Immunocore, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, NextCure, Novartis, Ocean Biomedical, Oncocyte, Oncternal Therapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revelar Biotherapeutics, Ribon Therapeutics, Roche Laboratories Inc, Sanofi, WindMIL Therapeutics, Xencor; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Merck; Data and Safety Monitoring Boards/Committees: EMD Serono Inc, Halozyme Inc, Novartis, Scorpius Holdings Inc. John V Heymach, MD, PhD — Advisory Committees: AstraZeneca Pharmaceuticals LP, BerGenBio ASA, BioAtla, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Curio Science, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Licensing/Royalties: Spectrum Pharmaceuticals Inc; Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Mirati Therapeutics Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc.
  
  MODERATOR
  Helena Yu, MD
  Medical Oncologist
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Therapeutics, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc; Research Funding to My Institution: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Novartis, Pfizer Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Taiho Oncology Inc.
  
  Release date: June 2024
  Expiration date: June 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.